Compare BGSI & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGSI | CNTA |
|---|---|---|
| Founded | 1990 | 2020 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | N/A | 2021 |
| Metric | BGSI | CNTA |
|---|---|---|
| Price | $178.30 | $23.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $38.50 |
| AVG Volume (30 Days) | 18.4K | ★ 1.6M |
| Earning Date | 02-25-2026 | 03-23-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $3,101,279,000.00 | $15,000,000.00 |
| Revenue This Year | $4.03 | N/A |
| Revenue Next Year | $26.52 | N/A |
| P/E Ratio | $308.32 | ★ N/A |
| Revenue Growth | 1.42 | ★ 118.88 |
| 52 Week Low | $136.81 | $9.60 |
| 52 Week High | $178.86 | $30.58 |
| Indicator | BGSI | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 69.84 | 43.38 |
| Support Level | $159.92 | $23.41 |
| Resistance Level | $175.19 | $26.51 |
| Average True Range (ATR) | 3.80 | 1.42 |
| MACD | 0.99 | 0.03 |
| Stochastic Oscillator | 90.70 | 40.16 |
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority, and Autoglassonly.com. In addition, the Company operates a third-party administrator, Gerber National Claims Services (GNCS), that offers glass, emergency roadside, and first notice of loss services.
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.